Elicera Therapeutics to Launch B-cell Lymphoma Therapy's Phase 2a Trial

06:25 AM EDT, 09/17/2026 (MT Newswires) -- Elicera Therapeutics (ELIC.ST) received approval from the Swedish Medical Products Agency to launch the Carma clinical study's phase 2a trial of its B-cell lymphoma therapy ELC-301. The clinical-stage cell and gene therapy company said Thursday it will enroll six patients in the current dose-expansion phase. The initial phase of the trial, which covered a dose-escalation study with 12 patients, was completed with no dose-limiting toxicities reported.